Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

Recruiting now · Phase 2

Conditions studied: Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)

In brief

This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.

Key facts

Study ID

NCT07745361

Run by

Monte Rosa Therapeutics, Inc

People needed

25

Starts

2026-08-01

Expected to finish

2028-04-01

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years
• A predicted life expectancy of ≥ 3 months and an ECOG performance status ≤ 1
• Have histologically or cytologically confirmed castration-resistant adenocarcinoma of the prostate without small cell histology and with androgen receptor (AR) mutations
• Have not had prior treatment with more than 1 prior taxane-based chemotherapy regimen for castration-resistant prostate cancer
• Have no prior treatment with an AR degrader, opevesostat, or similar therapy
• Has ongoing (chemical or surgical) androgen deprivation with serum testosterone < 50 ng/dL (< 1.7 nM)
• Has received prior treatment with poly(ADP-ribose) polymerase (PARP) inhibitor, if appropriate, or deemed ineligible to receive treatment by the Investigator, or has refused PARP inhibitor treatment
• Has received prior treatment with at least 1 line of ARPi
• Have disease measurable per Prostate Cancer Working Group 4 (PCWG4) criteria, with or without measurable disease by RECIST 1.1
• Be able to provide a tumor biopsy for biomarker analysis during the Screening period
• Have adequate organ function

You may not qualify if…

• • Have received prior chemotherapy, definitive radiation, or biological cancer therapy within 21 days before the first dose of study treatment or have any AEs that have failed to recover to baseline
• Have received prior therapy with a GSPT1 degrader that was discontinued due to an AE
• Have received prior auto-HCT and have not fully recovered from effects of the last transplant
• Have received allogeneic hematopoietic stem cell transplantation within past 6 months and/or have symptoms of graft-versus-host disease
• Current use of chronic systemic steroid therapy in excess of replacement doses
• Have clinically active central nervous system involvement and/or carcinomatous meningitis
• Have a confirmed history of (noninfectious) pneumonitis that required steroids
• Clinically significant cardiac disease

Where it is running

• START Los Angeles — Los Angeles, California, United States (enrolling)
• START New Jersey — East Brunswick, New Jersey, United States (enrolling)
• START Mountain Region — West Valley City, Utah, United States (enrolling)
• Kansas University Cancer Center — Kansas City, Kansas, United States
• University of Maryland Greenebaum Cancer Center — Baltimore, Maryland, United States
• Henry Ford — Novi, Michigan, United States
• XCancer Omaha — Omaha, Nebraska, United States
• Virginia Cancer Specialists — Fairfax, Virginia, United States
• Levine Cancer Institute — Charlotte, North Carolina, United States
• Lancaster Urology — Lancaster, Pennsylvania, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• University of Washington Medical Center — Seattle, Washington, United States
• Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
• Rocky Mountain Cancer Center — Colorado Springs, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.